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Abstract
Respiratory syncytial virus (RSV) is the leading cause of serious lower respira-
tory infection (ALRI)-related hospitalization in children worldwide, and a source of 
morbidity and mortality in high-risk adults. There are strong associations between 
RSV, persistent wheezing and childhood asthma. Despite extensive research, no 
effective treatment is available aside from supportive care. The trial of a formalin-
inactivated RSV vaccine in the 1960s resulted in priming the severe illness upon 
natural infection. Palivizumab, a monoclonal antibody approved for RSV prophy-
laxis in high-risk infants, has only moderately decreased hospital admissions due to 
RSV infection. Live-attenuated, vector, and protein-based vaccine candidates are 
being investigated in many clinical trials. Developing a vaccine remains challenging 
due to finding the right balance between adequate immunogenicity and attenua-
tion of vaccine. Here we review the clinical significance of RSV in infants, young 
children, high-risk adults, elderly population, pregnant women; clinical manifesta-
tions and consequences of RSV infection; the pharmacologic strategies currently 
available, the current stages of RSV vaccine clinical trials, different strategies, and 
major hurdles in the development of an effective RSV vaccine.
Keywords: respiratory syncytial virus (RSV), pediatric, respiratory infection, 
palivizumab, antiviral therapy, immuno-prophylaxis, RSV vaccine, clinical trials
1. Introduction
RSV, a member of the Paramyxoviridae family, is an enveloped, negative-
sense, single-stranded RNA virus [1]. Especially within the winter months, it is an 
important cause of morbidity and mortality among young children, the elderly, 
and immunocompromised individuals [2]. Infection is transmitted by either direct 
or indirect contact with respiratory droplets, and prior infection does not result in 
persistent immunity.
RSV accounts for approximately 2.1 million outpatient visits among children 
younger than 5 years old [3]. Additionally, there are 177,000 hospitalizations and 
14,000 deaths among adults older than 65 years due to RSV infection [4, 5] each 
year in the United States. Human studies have shown strong associations between 
RSV, persistent wheezing, and childhood asthma [6–8].
Symptoms usually begin 4–6 days after transmission and present with nasal 
congestion, rhinorrhea, fever, or cough. RSV is one of the leading causes of lower 
respiratory tract infection (LRTI), and can cause tachypnea, wheeze, hypoxemia, or 
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respiratory distress, resulting in an emergency department visit or hospital admis-
sion [9]. Males are more severely affected than females, and for reasons that are not 
fully elucidated, Native Americans and Alaskan Native children are more likely than 
children of other ethnicities to have severe infection requiring hospitalization.
To date, supportive care is the main treatment option for RSV admission [9, 10]. 
There is no vaccine approved for RSV prophylaxis in the general population. In 
1966, the first vaccine for RSV, a formalin-inactivated (FI-RSV) type, was devel-
oped. However, it resulted in vaccine-enhanced disease (VED). Among vaccinated 
infant, 80% developed severe bronchiolitis or pneumonia and two died, compared 
to only 5% for the placebo group [11]. There was increased eosinophilic and neu-
trophilic infiltration and mononuclear cells in the lung parenchyma found in the 
autopsies of two infants that died, which suggests a Th2-biased immune response, 
however the mechanism of the VED remains unclear [12].
RSV is composed of 10 genes encoding 11 proteins: small hydrophobic (SH) protein, 
nucleocapsid associated proteins N, P, L, M2–1, and M2–2, the matrix (M)  
protein, nonstructural proteins NS1 and NS2, glycoprotein (G), and fusion (F) pro-
tein. The SH, N, M2–2, NS2, G, and F proteins are the most commonly manipulated 
proteins in vaccine production (Figure 1). The SH protein inhibits cell apoptosis 
through inhibition of the TNF-α pathway [13]. The N protein initiates encapsidation 
of the genome, the M2–2 protein mediates the balance between transcription and 
RNA replication, and the NS2 protein inhibits host interferon (IFN) response [14, 
15]. G protein mediates viral attachment to the host cell, while F protein enables 
fusion of the virus [16, 17]. RSV A and RSV B, the two antigenic subtypes, differ in 
their amino acid sequence of the G protein and reactivity to antibodies, resulting in 
differences in disease severity [18]. Targeting the F protein is of particular interest, 
as it is highly conserved between the two antigenic subgroups.
In this chapter, we will discuss the current and candidate antiviral drugs and 
prophylactic agents against RSV infection and some of the ongoing clinical trials of 
RSV vaccines. Evaluation of drugs typically proceeds in a methodical order, from 
studies in healthy adults, to hospitalized adults, to older seropositive children, to 
Figure 1. 
Current and future options for RSV treatment or prophylaxis. No RSV vaccine is currently on the market, but 
diverse vaccine candidates, targeting different proteins within the RSV virion, are undergoing clinical trials.
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seronegative infants/toddlers. For purposes of this chapter, we will highlight the 
most recent trials where research is ongoing. We will also elucidate many of the com-
plex hurdles that have impeded progress in the development of an effective vaccine.
2. Available pharmacologic strategies
2.1 Ribavirin
Ribavirin, a synthetic guanosine analogue antiviral agent, was first synthesized in 
the 1970s. It is believed that ribavirin is phosphorylated intracellularly and can then 
disrupt purine metabolism by inhibiting inosine monophosphate dehydrogenase, 
thereby inhibiting nucleic acid synthesis. Furthermore, it promotes antiviral cytokine 
production and Type 1 T-cell mediated immune responses. Starting in 1993, the 
American Academy of Pediatrics (AAP) Committee on Infectious Diseases supported 
the use of Ribavirin for severe RSV infections. However, in 1996, the recommenda-
tion changed to “may be considered” [19]. Currently, the use of aerosolized Ribavirin 
is limited to immunocompromised patients with RSV due to the inconvenient route 
of delivery, which requires prolonged aerosol administration; risks for potential 
toxicity, such as teratogenic effects during pregnancy; cost of therapy; and need for 
hospital admission. The safety of oral ribavirin in moderately to severely immuno-
compromised adults with PCR-proven RSV infection was examined in a retrospective 
cohort study. The main outcome of this study was the rate of adverse events, and 
authors conclude that ribavirin is well tolerated in immunocompromised adults [20]. 
However, the rate of progression of disease from URTI to the LRTI was not measured. 
In another retrospective study, immunosuppressed patients were given either oral, 
intravenous, aerosol or a combination of these treatments and showed that ribavirin 
therapy reduces progression from RSV URTI to LRTI [21]. In a similar study, Khanna 
et al. reported that 32% of patients who were treated with ribavirin progressed to 
LRTI compared to 68% of the untreated group [22]. Their study showed that oral 
ribavirin therapy was likely as effective as aerosolized therapy. However, because of 
the sample size and retrospective nature, neither of these studies could determine 
the precise role of ribavirin therapy in this patient population. In addition, ribavirin 
is being used for Hepatitis C infection, in conjunction with an interferon agent [23]. 
Furthermore, a recent study showed that ribavirin inhibited Zika virus replication 
and Zika virus-induced cell death in mammalian cells [24].
2.2 ALS-008176
ALS-008176, a prodrug of a cytidine nucleoside analogue, decreased viral 
load and more readily cleared RSV than placebo in a randomized, double-blind 
clinical trial in healthy adults [25]. However, participants’ preexisting immune 
memory, which may promote RSV clearance, was not assessed [26]. A randomized, 
double-blind Phase I study assessing both a single and multiple ascending dosing in 
hospitalized infants (Clinicaltrials.gov identifier #NCT02202356) was completed in 
February 2018, but results have not been published yet.
2.3 Presatovir
During viral entry, the F protein undergoes conformational changes to fuse with 
the host cell membrane [17]. Presatovir (GS-5806) is an orally bioavailable agent 
that inhibits these conformational changes, thereby blocking viral fusion [27].  
It was found in a Phase 2a trial with healthy adults (Clinicaltrials.gov identifier 
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#NCT01756482) to reduce viral load and severity of disease. However, it also 
caused low neutrophil counts and increased levels of alanine aminotransferase [27]. 
Despite these adverse events and because of its promise as an efficacious antiviral 
agent, a Phase 2b, randomized, double-blind trial in RSV-infected hospitalized 
adults was completed in April 2017 (Clinicaltrials.gov identifier #NCT02135614). 
The primary outcome was the time-weighted average change in RSV load from 
baseline to Day 5. There appeared to be no significant differences between 
Presatovir and placebo (−0.77 vs. −0.89, respectively, p value = 0.46).
3. Currently available and under development immuno-prophylaxis
3.1 RSV-IVIG
RSV Immunoglobulin (RSV-IVIG, RespiGam) is a pooled hyperimmune poly-
clonal immunoglobulin preparation made from donors with high titers of anti-RSV 
antibodies. RSV-IVIG significantly reduced morbidity and mortality in high-risk 
infants [28]. It was initially licensed in 1996, but taken off the market in 2004, due 
to the need for long intravenous infusion sessions and supervision in a hospital 
setting, high volume doses resulting in fluid overload in already at-risk infants, and 
potential risk for blood-borne pathogens [29]. Furthermore, immunizations with 
live-attenuated viruses, such as the measles/mumps/rubella (MMR) vaccine, need 
to be postponed until 9 months after RSV-IVIG infusion.
ALX-0171 is an inhaled trivalent nanobody that targets the RSV F protein [30].  
A Phase I/IIa in RSV-infected infants and toddlers was recently completed in 
February 2016 (Clinicaltrials.gov identifier #NCT02309320). A Phase II dose rang-
ing study RSV-infected hospitalized infants was recently completed in May 2018. 
Results from both studies have not been published yet.
3.2 Palivizumab and motavizumab
Palivizumab (Synagis), developed by MedImmune (Gaithersburg, MD, USA) in 
1998, is the only currently approved prophylaxis agent against RSV infection [31]. It 
has been shown to reduce severe RSV infections by 55% and reduce RSV hospitaliza-
tions by 50%. Palivizumab is a humanized monoclonal IgG1 antibody that recognizes 
the RSV F protein and is administered intramuscularly monthly, for a maximum of 
5 months, during the RSV season. It has no significant adverse side effects and other 
required live-attenuated vaccines can still be administered. However, because of the 
high cost, it is selectively given to high-risk infants: preterm infants born at <29 weeks 
of gestation; infants with chronic lung disease (CLD) of prematurity defined as 
gestational age <32 weeks of gestation and requirement of supplemental oxygen for the 
first 28 days of life; hemodynamically significant congenital heart disease; and might 
be considered for neuromuscular disorders that impair the airway clearance [32, 33].
Motavizumab (MEDI-524, Numax), an affinity-matured derivative of palivi-
zumab, was shown to be more efficient than palivizumab with higher virus neutral-
izing effects [34]. However, it failed to receive FDA approval due to lack of greater 
clinical efficacy compared to palivizumab and cutaneous hypersensitivity reactions 
in some treated infants [35].
3.3 Suptavumab
Suptavumab (REGN2222) completed a Phase III trial in July 2017 (Clinicaltrials.
gov identifier #NCT02325791). It is a human monoclonal IgG1 antibody against 
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RSV-F [36]. 1177 preterm infants for whom palivizumab was not recommended 
were randomly assigned to one of three groups: Group 1 received one dose of 
intramuscular suptavumab and one dose of placebo, Group 2 received two doses of 
suptavumab, and Group 3 received two doses of placebo. There were no significant 
differences between the three groups in terms of the primary outcome of prevent-
ing medically attended RSV infection up to Day 150 [36]. All further development 
of Suptavumab has been stopped.
3.4 MEDI8897
MEDI8897 is another recombinant human monoclonal antibody with a modified 
Fc region that extends its half-life. MEDI8897 is being developed as RSV prophylaxis 
for all infants. The phase I (Clinicaltrials.gov identifier #NCT02114268) of study 
recruited 136 healthy adults, who received either MEDI8897 or placebo intravenously 
or intramuscularly, a single dose of 300–3000 mg. The half-life of the antibody was 
85–117 days across the groups [37]. The phase Ib/IIa of the study, recruited healthy 
preterm infants with a gestational age of 32–35 weeks. The antibody group received as 
single intramuscular dose of 10–50 mg MEDI8897. The half-life of the antibody was 
62.5–72.9 days. The authors concluded that the antibody has a favorable safety profile 
and can be administered as single dose during RSV season [38]. A Phase IIb trial in 
preterm infants’ ineligible for Synagis was completed in 2018 and there is a plan for the 
Phase III trial in healthy full-term and late pre-term infants in 2019.
4. RSV vaccines under development
To date, there is no vaccine against RSV. Developing a vaccine against RSV remains 
a challenge, as the proper balance is required in eliciting an immune response, while 
avoiding vaccine-enhanced disease. While many of the proteins within RSV are being 
manipulated in different vaccine strategies, RSV F comprises a highly conserved 
amino acid sequence called antigenic site II, between RSV-A and RSV-B antigenic 
subgroups, and has been considered an important antigen for an RSV vaccine.
Designing a vaccine against RSV requires careful considerations. Infants, the 
elderly, and pregnant women are the three targeted populations for RSV vaccine 
development [39]. Each of the three types of vaccines, live-attenuated, vector 
delivery, and protein based, have benefits and drawbacks that have to be considered 
when developing vaccine technology (Table 1). Live-attenuated vaccines contain 
extracted components of viral proteins and present antigens most similarly to the 
naturally occurring infection [40]. They stimulate both humoral and cell-mediated 
immune responses. Live-attenuated vaccines are employed against many viral 
diseases, like measles, rubella, polio, rotavirus, varicella, and yellow fever.
Taken from: Rezaee F, Linfield DT, Harford TJ, Piedimonte G. Ongoing develop-
ments in RSV prophylaxis: a clinician’s analysis. Curr Opin Virol. 2017;24:70–78.)
One major drawback of live attenuated vaccines is that they cannot be given to 
patients with compromised immunity including pregnant woman. Vector-delivery 
system vaccines utilize a non-pathogenic virus genome with inserted portions of 
RSV proteins. Similar to live-attenuated vaccines, these vaccines increase mucosal 
IgA and cellular immune responses, yet without the risk of insufficient attenuation 
[40]. Protein-based vaccines include whole-inactivated viruses, subunit antigens, 
and particle-based vaccines. Live-attenuated or vector vaccines hold the greatest 
promise for infants due to the risk of vaccine-enhanced RSV disease. Pregnant 
women and the elderly are not susceptible to vaccine-enhanced RSV disease, and 
therefore protein-based RSV vaccines are likely the most effective candidates [40].
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Live-attenuated, vector, and protein-based vaccines each possess advantages and 
disadvantages. Because non-replicating vaccines may elicit enhanced disease in RSV-
naïve infants during subsequent infection, replicating or vectored vaccines might be 
a better choice in this group [41, 42]. Additionally, active immunization for infants 
is challenging due to passive immunity received from the mother [43]. Because of 
these factors, different vaccines may be required for different target populations. 
Understanding these complexities is crucial in RSV vaccine advancement. We will 
now discuss in depth the different vaccine strategies and current clinical trials in 
each category. A list of the vaccine candidates is summarized in Table 2.
Vaccine type Current strategies
Live-attenuated M2–2 gene deletion
LID ∆M2–21030s
LID cp ∆M2–2
RSV D46/NS2/N/∆M2–2-HindIII
NS2 gene deletion
ΔNS2/Δ1313/1314 L
RSV 6120/∆NS2/1030s
SH gene deletion
MEDI–559
RSV cps2
Vector delivery system Adenovirus vector
GSK3389245A
GSK3003891A
VXA-RSV-f
Ad26.RSV.preF
PanAd3-RSV
Modified Vaccinia Ankara vector
MVA-RSV
MVA-BN
Protein-based Particle based vaccine
F-protein nanoparticle
Subunit vaccine
MEDI-7510
Table 2. 
Current vaccine candidates undergoing clinical trials.
Advantages Disadvantages
Live-attenuated
(For young infants 
and children 
<24 months of age)
• Induces immunity
• Does not exacerbate future RSV 
exposure
• Administered intranasally
• Need to obtain delicate balance 
between immunogenicity and adequate 
attenuation
Vector delivery 
system
(For young infants 
and children 
<24 months of age)
• Induced potent cellular and 
humoral responses in a primate 
model and preclinical studies
• Safer option than live attenuated 
vaccines in children with no risk 
of insufficient attenuation
• Prior exposure to the vector and 
immunological memory against com-
mon serotypes may reduce the immune 
response and limit their use
• The potential oncogenicity and pathoge-
nicity of some Adenovirus serotypes
Protein-based
(For pregnant 
women and elderly)
• Maternal immunization could 
increase transplacental antibody 
transfer and provide immunity 
for infants
• High risk of exacerbation for RSV-naïve 
infants
Table 1. 
Advantages and disadvantages of the main strategy categories for RSV vaccine development.
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4.1 Live-attenuated vaccines
The tragic results of the formalin-inactivated RSV vaccine in the 1960s spurred 
research in the development of live-attenuated vaccine candidates. The live virus 
has parts of the genome deleted and is passaged at gradually lower temperatures. 
Live-attenuated vaccines require a delicate balance: maintain sufficient viral 
genome RNA replication to illicit enough antibody response in RSV-naïve infants, 
yet with a low risk of deattenuation and no harmful effects [44]. Live-attenuated 
vaccines are, in theory, safe for RSV-naïve infants because it does not exacerbate 
future exposure to RSV. Furthermore, it may be administered intranasally, which 
can mimic a milder form of a natural infection, and lead to viral replication in the 
upper respiratory tract [40]. This will induce mucosal and humoral immunogenic-
ity, despite the potential presence of maternal antibodies acquired transplacentally.
Several live-attenuated RSV vaccine candidates have deletions of a large seg-
ment of the M2–2 gene. The M2–2 gene mediates the transition from transcription 
to RNA replication [14]. In vitro studies have shown that M2–2 gene deletion leads to 
decreased viral RNA replication, but increased F and G protein expression through 
transcription. This means that the virus is adequately attenuated, yet potentially 
could lead to augmentation of the neutralizing antibody response [14]. A Phase I 
study explored the safety of a LID ΔM2–2 vaccine, delivered intranasally to RSV-
seronegative infants (aged 6 to 24 months). This vaccine infected the subjects success-
fully, but the peak shedding titers were higher than wanted, and therefore the study 
was terminated [45, 46]. Further attenuation to the LID ΔM2–2 vaccine, to counter 
the high shedding titers, is currently under investigation. The LID ∆M2–21030s vac-
cine has a mutation conferring temperature sensitivity. A Phase I placebo-controlled 
study in RSV-seronegative infants aged 6 to 24 months (Clinicaltrials.gov identi-
fier #NCT02794870) completed in July 2017, showed that roughly 60% of vaccine 
recipients and 27% of placebo recipients had solicited adverse events. Conclusions 
regarding the LID ∆M2–21030s vaccine have not yet been made. A Phase I LID cp ∆M2– 
2 vaccine, which in comparison to the LID ∆M2–2 contains 5 amino acid substitu-
tions, was terminated early in seronegative infants 6 to 24 months of age due to 
indication that the vaccine “did not meet the protocol criteria for a good vaccine can-
didate” (ClinicalTrials.gov identifier #NCT02890381). We believe that this is because 
only 6/11 patients in the vaccine arm of the trial were infected with the vaccine virus 
from Study Day 0–28, thereby suggesting that there was not a strong enough immune 
response against the vaccine. Another vaccine candidate is RSV D46/NS2/N/∆M2–2-
HindIII that contains one point mutation in the NS2 and N proteins and a modified 
version of the M2–2 deletion [47]. A Phase I study in RSV-seronegative infants and 
children 6–24 months of age was completed in May 2018.
Aside from deleting the M2–2 gene, the NS2 gene is another potential “knock-
out” gene for a live-attenuated vaccine. The RSV NS2 gene is known to promote 
epithelial cell shedding and inhibit host IFN response [15]. ΔNS2/Δ1313/1314 L, 
a vaccine candidate with a deleted NS2 gene, is genetically stable and moderately 
temperature-sensitive [48]. Another candidate, RSV 6120/∆NS2/1030s, also has a 
deleted NS2 gene, in combination with the “1030s” missense mutation, which pro-
vides further restriction of replication. Both of these candidates are currently being 
assessed in both seropositive and seronegative children and infants (Clinicaltrials.
gov identifiers #NCT03422237 and #NCT03387137).
Strategies have also targeted the SH gene. The RSV SH gene has multiple func-
tions, including inhibiting cell apoptosis, inhibiting signals from TNF-α, and 
modifying membrane permeability [49]. One vaccine that has a complete dele-
tion of the SH gene, rA2cp248/404/1030∆SH, demonstrated restricted antibody 
response in the subjects, as well as viral genotypic and phenotypic instability 
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primarily due to reversion of the 1030 mutation [42, 48]. MEDI-559 differs from 
rA2cp248/404/1030∆SH by silent nucleotide substitutions throughout the viral 
genome [42, 50]. A Phase I/IIa trial studying the safety and efficacy of MEDI-559, 
showed a higher incidence of medically attended LRTI in RSV seronegative infants 
5 to <24 months of age and in infants 1 to <3 months of age regardless of baseline 
serostatus within 28 days, as compared to placebo [50]. RSV neutralizing antibod-
ies were detected in 59% of MEDI-559 recipients, in comparison to 9% of placebo 
subjects. Interestingly, this microneutralization response was lower than the 
rA2cp248/404/1030ΔSH vaccine’s response. Adverse events, most notably URTI, 
occurred in 67% MEDI-559 and 57% placebo recipients, which was not clinically 
significantly different. Further safety trials are warranted to determine the safety 
profile of MEDI-559 as there was increased incidence of medically attended LRTI.
In comparison to MEDI-559, RSVcps2 contains 5 nucleotide changes and 1 
amino acid substitution. The level of attenuation of RSVcps2 and MEDI-559 was 
shown to be similar in a study in seronegative chimpanzees [48]. This study also 
showed that it was temperature-sensitive and phenotypically and genetically 
stable. A Phase I trial in RSV-seronegative, healthy 6–24 month old children 
demonstrated that RSVcps2 is safe and effective [51]. Furthermore, unlike 
MEDI-559, medically attended LRTI was not observed. There were no signifi-
cant differences in the number of adverse events between the experimental and 
control groups. However, in comparison to rA2cp248/404/1030ΔSH, RSVcps2 
had decreased levels of replication and immunogenicity. The study investiga-
tors believe that this is due to the 37 silent nucleotide differences between the 
two vaccine candidates [51]. An ideal candidate would therefore combine the 
genetic stability of RSVcps2 and the greater replication and immunogenicity 
of rA2cp248/404/1030ΔSH. Other ∆SH vaccine candidates include OE4 (RSV-
A2-dNS1-dNS2-ΔSH-dGm-Gsnull-line19F) and DB1 (RSV-A2-dNS-ΔSH-BAF), 
which have both been found to be immunogenic in cotton rats [52, 53].
4.2 Vector delivery systems
Vaccine technology is currently utilizing adenovirus and non-pathogenic viral 
genomes that can act as immune potentiators of delivery systems. These vaccines 
contain inserted portions of RSV F, N, and M2–1 proteins [54]. Vector vaccines 
increase mucosal IgA and cellular immune responses similar to live-attenuated vac-
cine candidates, yet without the risk of insufficient attenuation [55]. Furthermore, 
adjuvants used with these vector vaccines could potentially enhance the immune 
response to the vaccine [56].
GlaxoSmithKline’s ChAd155-RSV (GSK3389245A) and GSK3003891A are RSV 
vaccine candidates encoded by a chimpanzee-derived adenovector. A Phase II trial 
(Clinicaltrials.gov identifier #NCT02360475) evaluating GSK3003891A in healthy, 
non-pregnant women aged 18–45 years was recently completed. The study showed 
that GSK3003891A is both safe and immunogenic. However, a Phase II trial in healthy 
pregnant women and infants born to vaccinated mothers was canceled due to instabil-
ity of the PreF antigen during manufacturing. A Phase I study investigating ChAd155-
RSV in healthy adults aged 18 to 45 years was recently completed (Clinicaltrials.gov 
identifier #NCT02491463), and a Phase II study in RSV-seropositive infants aged 
12–23 months is underway (Clinicaltrials.gov identifier #NCT02927873). Another 
adenoviral-vector based RSV vaccine candidate, VXA-RSV-f, expressing the F-protein 
and a dsRNA adjuvant, is recently completed a Phase I, placebo-controlled, dose-
ranging study, using subjects aged 18–49 years. Results have not been released yet.
Adenoviruses of serotype 26 (Ad26) are engineered to comprise a nucleotide 
sequence encoding RSV F protein, which showed efficacy against RSV in mice and 
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cotton rats [57]. Two Phase I, placebo-controlled studies assessed the administra-
tion of Ad26.RSV.FA2, given either once or twice, followed by Ad35.RSV.FA2, and 
vice versa, to adults aged 18–50 years. Ad26.RSV.FA2 was shown to be safe and well 
tolerated. There was also increased humoral and cellular immunity for 6 months. 
Ad26.RSV.preF differs by 5 amino acids and contains the pre-fusion conformation 
stabilized F protein, and showed increased immunogenicity in comparison to Ad26.
RSV.FA2 in pre-clinical studies [58]. It is currently undergoing a Phase II clinical 
trials in adults aged 18–50 years and RSV-seropositive toddlers aged 12–24 months 
(Clinicaltrials.gov identifier #NCT03303625) and in healthy adults greater than 
age 60 (Clinicaltrials.gov identifier #NCT03339713). PanAd3-RSV, a vaccine 
based on the RSV viral proteins F, N and M2–1 encoded by Simian Adenovirus, 
completed a Phase I trial in subjects 18–75 years of age (ClinicalTrials.gov identi-
fier #NCT01805921) in 2015, alongside a Modified Vaccinia Virus Ankara (MVA) 
non-replicating vector vaccine candidate. Both of these vector vaccines contain RSV 
viral proteins F, N and M2–1.
PanAd3-RSV and MVA-RSV were both safe and effective in cotton rats, mice, 
and calves [59] and immunogenic in a primate model [54]. Most adverse effects 
were mild to moderate, self-limiting at the site of injection and the study concluded 
that the vaccine was safe and immunogenic [60]. Despite the promising results, no 
current clinical trial is investigating these vaccine candidates. MVA-BN (modified 
Vaccinia Ankara—Bavarian Nordic) is another MVA-based vaccine undergoing 
investigation. In August 2018, Bavarian Nordic announced that in a Phase II trial 
in older adults the MVA-BN vaccine elicited broad antibody and T cell responses to 
both RSV subtypes that lasted 6 months. Furthermore, a booster shot 1 year later 
again initiated a robust cellular immune response [61].
4.3 Protein-based vaccines
Pregnant women and the elderly are not susceptible to vaccine-enhanced RSV 
disease like infants, and therefore RSV protein-based vaccines are most likely 
the most effective candidates. Protein-based vaccine candidates include whole-
inactivated viruses, subunit antigens, and particle-based vaccines. Vaccinating a 
pregnant woman can provide passive immunity to the fetus, as RSV-neutralizing 
antibodies have been shown to pass from mother to fetus in utero [43]. The higher 
RSV neutralizing antibody in cord blood was associated with reduced risk of hos-
pitalization and disease severity in RSV infection has been shown by several studies 
[62, 63]. A recent comprehensive study measured multiple serum neutralizing RSV 
of the infants presented with primary RSV infection and did not find a direct rela-
tionship between the disease severity and level of most of anti–respiratory syncytial 
virus (RSV) antibody titers. However, they found a significant inverse relationship 
between antibody titer to RSV F protein and disease severity [64]. This is particu-
larly important as the post-fusion form of RSV F protein has been used in clinical 
trial [65]. Additionally, experimental studies have shown that RSV infection during 
pregnancy can alter the offspring’s postnatal immunity and airway hyperresponsive-
ness [66]. Therefore, a protein-based vaccine not only provides immunization for the 
pregnant woman, but also for the fetus in utero and the offspring once baby is born.
MEDI-7510 is a subunit RSV vaccine candidate that contains the post-fusion F glyco-
protein, with or without a glucopyranosyl lipid A (a synthetic TLR-4 agonist) adjuvant 
[67]. A Phase IIb trial in adults aged 60 and older showed that the vaccine candidate was 
immunogenic but did not protect the study population from RSV illness [68].
Novavax’s RSV F-protein nanoparticle vaccine has been trialed in a few Phase I 
and II studies in healthy human adults and one study of subjects 24 to <72 months 
of age, and was found to be well-tolerated and immunogenic in all studies [69, 70]. 
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This vaccine consists of nearly the full-length F glycoprotein. This nanoparticle 
vaccine prompted transplacental antibody transfer within a guinea pig model [71]. 
Furthermore, in a Phase II study in healthy women of child-bearing age, the vaccine 
was well tolerated. The peak of Anti-F IgG antibody was day 14 and persisted for 
3 months, optimal for administration during the third trimester [72]. Recently, 
the immunogenicity, with an aluminum adjuvant, was evaluated in a Phase II trial 
(Clinicaltrials.gov identifier #NCT02247726) in healthy third-trimester pregnant 
women. In this study in pregnant women, the primary outcome measures were 
safety and immunogenicity of the vaccine, as well as its impact on the number of 
infants with medically-attended RSV LRTI and age of onset of the infection. No 
results have been posted for this study. However, a Phase III study investigation in 
the same study population is set to be completed in 2019, thereby suggesting that 
the Phase II trial met its goals.
5. Conclusions
RSV is one of the most common causes of lower respiratory disease in infants, 
young children, and the elderly. Treatment is currently limited to support-
ive care, such as supplemental oxygen, bronchodilators, or corticosteroids. 
Palivizumab prophylaxis is currently restricted to high-risk infants. There 
is currently no vaccine to prevent RSV infection. There are many challenges 
associated with developing an RSV vaccine candidate. When developing a live 
attenuated vaccine, an equilibrium must be struck between adequate immu-
nogenicity and attenuation of the virus. Non-replicating vaccines, like in some 
vector-delivery systems and protein-based vaccines, can enhance RSV infection 
in RSV-naïve infants. Therefore, it may be necessary to develop separate vaccines 
for each at-risk population: neonates and young children, pregnant women, and 
the elderly. One highly promising strategy appears to be maternal immunization 
with a nonreplicating vaccine, as this may provide protection during the first few 
months of life in the neonate.
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